One World Hull

Shoppers Delight

Archives for: August 19, 2017

Jeremy Goldstein encourages companies switch to knockout options

Posted on by

The popularity of stock options is increasingly losing interest by those who run companies. While many factors have played a role to their decline over the last 10 years, three concerns have been raised including: the expenses associated with the stock option often is more than the value perceived by the employees, When a company’s stock value falls drastically and the options have no chance at being-in-the-money, the company faces an expense and must deal with overhang, with no way of getting rid of them and finally stock options do not give employees any drive to work harder. Learn more about Jeremy Goldstein: https://www.slideshare.net/JeremyGoldstein14/ and https://www.slideshare.net/JeremyGoldstein14/22nd-annual-naspp-presentation-2014

Stock options recipients benefit from options. Employees only benefit if the stock price goes up and options strongly encourage employees to increase stock price, specifically those in high-growth industries. Stock options are easier to explain to employees.

Options are easier to deliver than the other forms of equity compensation. Companies must find a way to use stock options while decreasing the compensation expense that is part of their grant and to solve the problem of continuing expenses and overhang, especially when the option significantly falls.

To solve most of these problems, Jeremy Goldstein offers the idea of the “knockout” stock option. These options will be forfeited if the price tied to the option falls below a certain point. Jeremy Goldstein suggests that in order to avoid the automatic forfeiture, knockout options should only be forfeited if the price falls below a set threshold for a length of time such as 5 or 10 trading days.

Jeremy Goldstein is one of New York’s top corporate lawyers, amassing more than 15 years of experience as a business lawyer.

Goldstein established his own law firm in New York. He has been a part of many of the country’s largest corporate transactions of the last 30 years.

George Soros: The Strong-Willed Philanthropist

Posted on by

George Soros is renowned as one of the richest philanthropists in the U.S.A. Soros has given more than $12 billion to charity. His donations have been channeled to supporting organizations that fight for transparency, accountable government, freedom of expression, and societies that lobby for equality and justice. Soros’s has also focused his charity to those societies that are discriminated against.

Soros’ Life Background

Soros experienced intolerance at a tender age. Born in 1930 Hungary, Soros had to endure the atrocities of the Nazi Occupation which included the murder of more than 500,000 Jews. His Jewish family was lucky to survive after getting false identity documents, hiding their backgrounds, and assisting others to flee from the wrath of the Nazis. Soros recalls that he and his family resisted a tyrannical force and was able to prevail. Soros fled to London in 1947 and got a part time job at the railway station and at a night club. The earnings from these jobs helped him pay for his college fee at the “London School of Economics”. He later emigrated to U.S.A. to venture into the industry of finance where he amassed a great fortune.

How Soros Started His Career

In 1970, Soros established a hedge fund and named it the “Soros Fund Management“. This firm helped Soros to be listed among the most prosperous investors in the U.S.A. Soros injected his fortune into the Open Society Foundations- a collection of partners, projects, and foundations in over 100 countries.

How Soros Begun Philanthropy

Soros’ first act of philanthropy was in 1979 when he sponsored black South Africans who were facing apartheid. During the 1980s, Soros helped the Communist Eastern Bloc to exchange ideas by donating photocopiers to assist the reprinting of banned texts. Soon after the Berlin Wall fell, Soros established the Central European University to encourage critical thinking. He promoted cultural exchanges which played a central role in assisting the Soviet society to be open to the world.When the Cold War ended, Soros expanded his voluntary services to Africa, Asia, and the U.S.A. Soros committed his efforts to making societies more transparent, democratic, and accountable.

What Is Open Society?

The phrase open society was first described by Henri Bergson but popularized by Karl Popper in one of his most popular books, “The Open Society and Its Enemies (1945)”. According to Popper, totalitarian systems like Nazism and communism have one common denominator; they claim to possess the truth. Because the truth cannot be accessed by mankind, most of these ideologies turn to oppression to impose their ideologies on society. Popper further identified that no single person possesses the truth. Since different people view the world differently, there are institutions in place to ensure all these people live peacefully together. Such institutions ensure the freedom of speech and choice. Popper referred to this social structure as open society. He also held that totalitarian concepts were its greatest enemies.

Vijay Eswaran’s Journey Manifests His Capabilities in Leadership, Hard Work, Persistence, and Generosity

Posted on by

Vijay Eswaran is a multi-role individual. He is an author, businessman, motivational speaker, and a philanthropist. He attended the London School of Economics where he earned a socio-economic degree. Vijay took up menial jobs in the United Kingdom right after college. While still in the United Kingdom, he became aware of the binary marketing system. Vijay started working for Synaptics, doing multilevel marketing on a part-time basis.

At the same time, he enrolled for a course to obtain CIMA certification. He also enrolled at the Southern Illinois University where he attained an MBA. Upon returning to Malaysia, Vijay got more interested in multilevel marketing. Thus, he decided to create Q1 Group.

The QI Group

The QI Group focuses on multilevel marketing with interest in numerous industries. The firm has its hands on telecommunications, wellness, training, luxury products, and corporate investments. The company started on a very humble level, particularly when a crisis hit Asia in 1998.

Vijay’s passion and dedication so the firm move from the murky waters to record tremendous growth. His leadership skills and ability to hire the right people prompted growth that formed the internationally recognized firm that it is today. Learn more about Bernado Chua: https://twitter.com/vjayeswaran?lang=en

Currently, the QI Group has a presence in almost ten countries and regional offices in Thailand, Hong Kong, and Singapore. As a strategy for expanding its operations, the firm recently ventured into the education sector by launching a Malaysian-headquartered University. QI Group is not relenting as it is scheduled to start a QI City, which will have a shopping mall, a campus, a teaching hospital, and hostels.

Publications, Public Speaking, and Philanthropy

Vijay Eswaran has shared his experiences and expertise in multiple business and management forums as a motivational speaker. Such conferences include the 6th Pravasi Bharatiya Divas as well as the World Economic Forum. His publications include In the Sphere of Silence, In the Thinking Zone, 18 Stepping Stones, and Two Minutes from the Abyss.

Vijay Eswaran carries out his philanthropic missions through RHYTHM Foundation, QI Group’s corporate social responsibility branch. He also established another foundation, Vijayaratnam Foundation. He is actively involved in community programs and funding non-profits.

How Oncotarget is Helping People

Posted on by

Oncotarget is the brainchild of Mikhail Blagosklonny who wanted to make sure that he was helping people instead of making things harder for them. He worked hard in the cancer industry and has been one of the most successful oncologists in his field. He tried to make sure that he had something that he could use to make things better for people and that was a huge part of the practice that he has. He has always been dedicated to the field that he is in and he knows a lot about treatment of cancer so that he can help people with the issues that they are having. All of this is a result of the things that Mikhail Blagosklonny knows how to do and the way that he runs his own practice. He is confident in his abilities as a doctor and has made many good choices.

When Mikhail Blagosklonny first developed Oncotarget, he was able to help people with the options that they had. He wanted other doctors to know about Oncotarget and showed them the way that the peer review publication would work. He included oncologists at first but then realized that including other specialists would be able to make Oncotarget better and could help people with the options that they had. This worked out for Mikhail Blagosklonny because he is now able to make things better for people and there are many specialists who regularly contribute to Oncotarget with the research that they have been able to do.

All of this meant that Mikhail Blagosklonny was able to find new information. For example, he learned about immune therapy. This is a therapy that can be done using rejuvenation. Without the help of a cosmetic surgeon, Mikhail Blagosklonny would have never known about it. Thanks to Mikhail Blagosklonny, many people are now getting the immune therapy that they need from the cancer treatments that they are having. Mikhail Blagosklonny is regularly practicing immune therapy and that has helped people. All of this has been a result of Oncotarget and the different things that Mikhail Blagosklonny is capable of doing.

All you should know about Clay Siegall

Posted on by

Within the business park in Bothell, we have Seattle Genetics. The business park makes head office for the biotech company whose study centers human antibodies. They even have a sculpture to show for it just outside their business premises. They would them convert the results of the study into drugs. They have been in operations since their birth 29 years ago. In their technology, antibodies involved are used to develop toxin to cancer cells. The cancer cells would get destroyed from within. Success in their research would see them shoot up into the big leagues.

The company has recently increased its market value to $10 billion with its 900 staff members. It aims at becoming a big pharmaceutical company despite its being the largest biotech in Washington. They have put so much into their research in terms of effort and money. They intend to increase their staff members by 200. In the words of the company’s president and co-founder, Clay Siegall, the biotech is going across continents. He went ahead to list the drugs under its research that will make it a multiproduct oncology company. One that would proceed in greatness instead of selling out to other big companies. His desire is graduate his concerns from drug creation to handling the marketing technicalities for their new drugs. This is unlike their previous operations where they partnered with Takeda Oncology. This was because they needed to come up with money to boost research of its flagship drug, Adcentris. Adcentris is meant for treatment of cancer of the lymph system. After their relationship with Takeda, Siegall decided to perform its own international marketing. He acquired knowledge of this from interactions with Takeda.

Seattle genetics has experienced much growth recently. It had over $418 million sales last year. The company has not made much profit yet but with its recent successes, its value increased by more than half. They even had their stock price increase from $20 to $66 a share. There are experts who expect that with this rise in value, the company may later sell out to another. There are those that disagree saying that they deserved it because of their intense efforts into research. The company has also majored its research on ADC whose target is antigens. Their technology is meant to attach to cancer cells, killing them from within without causing damage to normal body tissues. Their research should help reduce the damage caused in chemotherapy and radiation.

There are four very promising drugs by the company: Adcentris which is meant to treat Hodgkin lymphoma and that was approved by the FDA, there is drug 33A that aims at treating acute myeloid leukemia. There is also drug 22ME meant for bladder cancer and for breast cancer, they have drug LIV1. Director of Life science Washington, Leslie Alexandre believes that the bigger the company in biotech, the more the confidence. Specialized scientists are a very difficult group to employ for these companies. She said this to prove to investors that they are doing well around there.

Clay Siegall Bio

This George Washington University Graduate is the founder and president of Seattle Genetics, a biotech company. He has led the company for over 29 years since its birth. Under his leadership, the company has created varying treatments for anti-body based cancer. He helped in creation of ADCENTRIS a drug that has been approved by the FDA.

Before Seattle Genetics, Clay Siegall worked at Bristol-Myers, a research institute for pharmaceuticals and also at the National Cancer Institute. He graduated with a Ph.D. from Washington campus and also graduated from Maryland College with a Bachelors in Science in Zoology. Clay Siegall is also an author with more than 70 items published.